Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14477117 | 0.95 | CYP4F2 (0.53) | CYP4F2CYP4A11SMN1; SMN2LMNAMAPT | |
| SCHEMBL31324165 | 0.92 | SMN1; SMN2 (0.56) | CYP4F2CYP4A11SMN1; SMN2LMNAMAPT | |
| SCHEMBL13280077 | 0.88 | MAOB (0.66) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2060889 | 0.87 | SMN1; SMN2 (0.60) | CYP4F2CYP4A11SMN1; SMN2LMNAMAPT | |
| SCHEMBL4113212 | 0.84 | CYP4F2 (0.76) | CYP4F2CYP4A11SMN1; SMN2LMNAMAPT | |
| SCHEMBL5444853 | 0.84 | PPARD (0.54) | LMNAHSP90AB1RXRARXRBRXRG | |
| SCHEMBL11466806 | 0.84 | LMNA (0.51) | CYP4F2CYP4A11SMN1; SMN2LMNAMAPT | |
| SCHEMBL4597184 | 0.83 | PSEN1 (0.70) | CYP4F2CYP4A11SMN1; SMN2LMNAMAPT | |
| SCHEMBL846548 | 0.83 | LMNA (0.74) | CYP4F2CYP4A11SMN1; SMN2LMNAMAPT | |
| SCHEMBL7474677 | 0.82 | MAOB (0.48) | MAPTHDAC1HDAC8MAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107033006-B | Preparation method of diaryl ketone | 长沙理工大学 | 2018-12-18 | — | — | CN | claimed |
| CN-108440299-A | A method of preparing 4- nitro benzophenone class compounds | 长沙理工大学 | 2018-08-24 | — | — | CN | claimed |
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250302803-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-10-02 | — | — | US | disclosed |
| US-12357610-B2 | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2024233642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-3774805-B1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | SERVIER LAB (FR) | 2024-01-10 | — | — | EP | disclosed |
| US-20230414566-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-12-28 | — | — | US | disclosed |
| US-11806333-B2 | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-11-07 | — | — | US | disclosed |
| CN-111936499-B | Heterobicyclic inhibitors of MAT2A and methods for treating cancer | 法国施维雅药厂 | 2023-09-19 | — | — | CN | disclosed |
| US-11524960-B2 | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | SERVIER PHARMACEUTICALS LLC (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2004002943-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-01-08 | — | — | WO | disclosed |
| US-6034106-A | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity | MERCK & CO., INC. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0906310-A4 | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO INC (US) | 1999-09-01 | — | — | EP | disclosed |
| EP-0906310-A1 | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997046556-A1 | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| US-5457212-A | Process for the preparation of enantiomerically pure thienopyran derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-10-10 | — | — | US | disclosed |
| US-5302752-A | Acetic acid derivatives and their production | ETHYL CORPORATION (US) | 1994-04-12 | — | — | US | disclosed |
| EP-0493048-A1 | The process for the preparation of enantiomerically pure thienopyran derivative | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-07-01 | — | — | EP | disclosed |
| EP-0426333-A2 | Acetic acid derivatives and their production | ETHYL CORPORATION (US) | 1991-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357610-B2 | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | AADAC, GABRB2, GABARAPL2 | CYP4F2 854/4885CYP4A11 1195/4885SMN1; SMN2 995/4885 |
| US-20250302803-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | AADAC, GABRB2, GABARAPL2 | CYP4F2 854/4885CYP4A11 1195/4885SMN1; SMN2 995/4885 |
| US-11524960-B2 | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | MAT2A, MAT2B, MAT1A | CYP4F2 824/4885CYP4A11 2929/4885SMN1; SMN2 1469/4885 |
| US-20230414566-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | AADAC, GABRB2, GABARAPL2 | CYP4F2 854/4885CYP4A11 1195/4885SMN1; SMN2 995/4885 |
| US-11806333-B2 | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | AADAC, GABRB2, GABARAPL2 | CYP4F2 854/4885CYP4A11 1195/4885SMN1; SMN2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.